Figure 1 Clinical case study

Slides:

Advertisements

Similar presentations

Safe and Effective Re-Induction of Complete Remissions in Adults with Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy Davila ML et al. Proc.

Advertisements

Kochenderfer JN et al. Proc ASH 2013;Abstract 168.

Patrick Stiff MD Coleman Professor of Oncology

Maude et al. BLOOD, 25 JUNE 2015 x VOLUME 125, NUMBER 26

The Role of Immunotherapy for the Treatment of Hematologic Malignancies Patrick Stiff MD Coleman Professor of Oncology Loyola University Medical Center.

PET Criteria for Response Assessment After Completion of Therapy for Aggressive NHL and HL Definition of a positive PET scan (Visual assessment is adequate,

chimeric antigen receptor T-cell therapy for ALL

Professor John Gribben Barts Cancer Institute

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 2 Response after initial increase in total tumour burden

Immunotherapy for lymphoma: The time is now

Nonengraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without Chimerism Gerald A. Colvin, David Berz, Muthalagu.

Figure 1 Concept of the therapeutic index

Figure 3 Risk-adapted and response-adapted

Figure 2 New functional imaging techniques in lymphoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Examples of functional imaging biomarkers in two DCA responders

Figure 2 Neoantigen presentation in the tumour microenvironment

Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 3 Intracranial targeting of high-grade gliomas

Figure 2 Three-step approach to the assessment and management

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Research Techniques Made Simple: CAR T-Cell Therapy

Figure 1 Chimeric antigen receptor (CAR) structures

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Figure 5 Identification of mucinous carcinoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Volume 25, Issue 1, Pages (January 2017)

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 CAR-T-cell design

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 4 Combination immunotherapeutic approaches with imatinib

Figure 2 The association between CD8+ T‑cell density of the tumour

Changes in PMR-AS, CRP levels, and GC dosage (prednisone) following TCZ therapy in 7 patients with PMR. Since our series included patients with long duration.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Volume 25, Issue 10, Pages (October 2017)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Therapeutic targeting of the B-cell receptor (BCR)

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Fig. 2. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral blood. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral.

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

CAR-T cells: New HOPE FOR CANCER PATIENTS

Figure 4 New PET radiotracers in lymphoma

Figure 2 Approaches to improve CAR-T-cell therapy

Figure 4 11C-PK11195-PET scans showing the evolution of neuroinflammation in a patient after stroke Figure 4 | 11C-PK11195-PET scans showing the evolution.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Variations between planned and delivered doses of radiation

Volume 18, Issue 4, Pages (April 2010)

Figure 2 Biologics that target CD4+ T helper (TH)-cell subsets

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Volume 21, Issue 4, Pages (April 2013)

Volume 23, Issue 1, Pages (January 2015)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Foroud shahbazi Pharm.D

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Figure 2 Assessment of systemic disease activityTc99 scintigraphy (A) and fluorodeoxyglucose PET imaging (B, C) at disease onset 2 years before acute deterioration.

Blood Tfr cells are indicators of ongoing humoral activity.

Figure 4 Molecular signalling and immunological

Percentage of patients achieving remission by conversion to ACPA seronegative status. Percentage of patients achieving remission by conversion to ACPA.

by Jennifer N. Brudno, and James N. Kochenderfer

Systemic inflammation in patients with severe neurotoxicity (NTX).

Presentation transcript:

Figure 1 Clinical case study Figure 1 | Clinical case study. The findings of key clinical assessments are shown for a representative patient with cytokine-release syndrome and chimeric antigen receptor (CAR)-T-cell-related encephalopathy syndrome after anti-CD19 CAR-T-cell therapy for refractory diffuse large-B-cell lymphoma. a | The graph shows the patient's maximum temperature (Tmax), maximum heart rate (HRmax), minimum systolic blood pressure (SBPmin), minimum oxygen saturation (O2 satmin), and serum C-reactive protein (CRP) level recorded on each day after anti-CD19 CAR-T-cell therapy. The anti-IL-6 receptor antibody tocilizumab was administered on days 1, 3, and 5 (arrows) for the treatment of hypotension, hypoxia, and encephalopathy, respectively. b | Handwriting samples and mini mental status exam (MMSE) scores obtained on days 4, 5, and 6 after CAR-T-cell therapy; note how the patient's handwriting was markedly impaired on day 5, despite only a small decrease in their MMSE score. c | 2-[18F]fluoro-2-deoxy-d-glucose PET images showing the retroperitoneal lymph nodes and ileocolic region harbouring lymphoma at baseline (highlighted in red circle; bottom left), and loss of tracer uptake indicative of induction of disease remission at 30 days after infusion of CAR T cells (bottom right). Neelapu, S. S. et al. (2017) Chimeric antigen receptor T‑cell therapy — assessment and management of toxicities Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.148